// App-Quantinova.ai

262 : Docetaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC): Cost of care for Medicare and commercially insured men.

Researchers

Presenter

  • Andrew J. Armstrong

Principal Investigators

  • Cat N Bui

  • Kate Fitch

  • Tia Sawhney

  • Bruce Brown

  • Scott C Flanders

  • Peter St. John Francis

  • Mark A. Balk

  • Julie Deangelis

  • James Chambers

Medical Centers

  • Duke Cancer Institute, Duke University and the Department of Defense Prostate Cancer Clinical Trials Consortium, Durham, NC

  • Astellas Pharma, Inc., Northbrook, IL

  • Milliman, Inc., New York, NY

  • Astellas Pharma, Inc., Northbrook, IL

  • Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc., Northbrook, IL

  • Medication, Inc., San Francisco, CA

  • Tufts Medical Center, Boston, MA

Locations

  • United States

Companies

  • Astellas Pharma Inc.

  • Astellas Pharma US,

  • Medivation, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Phosphatase and tensin homolog

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved